AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02371486 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Ultrasound Scan
Description: Scanning the uterus with the ultrasound probe . Transvaginal ultrasound usually produces better and clearer images of the female pelvic organs, because the ultrasound probe lies closer to these structures.~The transvaginal ultrasound probe is thin, about 2cm diameter. The probe is covered with a disposable protective sheath. A small amount of ultrasound gel is placed on the end of this probe. The probe is then gently inserted a short distance into the vagina.
Study NCT02703363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Study NCT00872625 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT02371486 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IVF Cycle
Description: Controlled ovarian hyperstimulation, followed by Human chorionic Gonadotropin ( hCG) administration, Ovum Pickup and Embryo transfer
Study NCT02371486 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: IVF Cycle
Description: Controlled ovarian hyperstimulation, followed by Human chorionic Gonadotropin ( hCG) administration, Ovum Pickup and Embryo transfer
Study NCT04478786 — intervention group
Intervention type: OTHER
Intervention: Focus group discussion
Description: There is no intervention. This is a qualitative piece of work only.
Study NCT00467363 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetylsalicylic-acid (aspirin)
Description: 81mg of low-dose aspirin plus 400micrograms of folic acid.
Study NCT00467363 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Folic acid
Description: 400micrograms of folic acid.
Study NCT00872625 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiosurgery
Study NCT02078791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox infiltration
Description: botox cervical infiltration in a group
Study NCT02078791 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychology therapy
Description: Psychology problem solving therapy lead by specialized nurses.
Study NCT02078791 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Botox infiltration & psychology therapy
Description: Botox infiltration in cervical region and psychology problem solving therapy lead by specialized nurses.
Study NCT02703363 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT04453683 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Air-Q. ILA insertion of proper size
Description: Success of fiberoptic guided intubation throuhgh Air Q supraglottic airway device
Study NCT04453683 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ILMA insertion of proper size
Description: Success of fiberoptic guided intubation throuhgh ILMA supraglottic airway device
Study NCT00634556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa solution 2mg/ml for i.v. use
Description: 2mg/mL in normal saline
Study NCT00634556 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: normal saline
Study NCT00742456 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose solution
Description: single oral intake of 250 ml glucose solution (75gr sugar in 250ml of water)
Study NCT00742456 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single intake of placebo solution (250ml of sweet flavored water, no sugar added), orally
Study NCT00574652 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Proleukin
Description: 3 millions IU/day from day 1 to 5 every 21 days will be carried out at W1, W3, W6, and W9)
Study NCT02034591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Study NCT02034591 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Boost Plus
Study NCT00327535 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Description: According to the approved local label (6.75 micrograms/kg every 3 weeks, or 2.25 micrograms/kg every week)
Study NCT03036878 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ReNu
Description: ReNu is an allograft tissue composed of particularized amniotic membrane and cell from the amniotic fluid.
Study NCT04355286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemotrizinol
Description: Market-image topical sunscreen formulation containing BEMT (6%)
Study NCT04848805 — intervention group
Intervention type: PROCEDURE
Intervention: liver transplantation
Description: total hepatectomy material was examined by pathology laboratory
Study NCT00957853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: First dose of 400 mg/m\^2 by vein on Days 1 and 8 over 2 hours, second dose of 250 mg/m\^2 on week 2 and 3 (if applicable) given over 1 hour.
Study NCT00327535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: 6.3 micrograms/kg every 3 weeks
Study NCT00957853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMC-A12
Description: 6 mg/kg/week by vein on Days 1 and 8 over 1 hour on weeks 1 and 2 and 3 (if applicable).
Study NCT00957853 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical tumor resection
Description: Surgical tumor resection on Day 10.
Study NCT00327535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: 9 micrograms/kg every 3 weeks
Study NCT00327535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: 12 micrograms/kg every 3 weeks
Study NCT01732692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOVIPREP
Description: MOVIPREP solution
Study NCT01732692 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: MOVIPREP
Description: MOVIPREP solution
Study NCT02158572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG200-15
Description: Transdermal contraceptive delivery system
Study NCT00816036 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Guideline Implementation
Description: 1. Enhanced academic detailing of staff nurses (face-to-face training, feedback on group performance, and periodic check-ins with both nurse managers and peer leaders); 2. Adaptation of the computerized information system (modified nursing admission database that includes pertinent questions about smoking, computerized quick orders for smoking cessation medications), 3) Patient self-management support (self-help materials, fax referral of motivated patients to state quit line), and 4) nursing peer leaders on each study unit.
Study NCT04068883 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Q collar
Description: An externally-worn medical device that applies mild jugular compression
Study NCT01027156 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Exercise
Description: In this study, participants will be instructed to sprint maximally for a period of 30 seconds. Following 30s rest, the participants will be instructed to repeat this procedure a further 3 times. This equates to 2 minutes of maximal effort sprinting interspersed with 2 minutes recovery. Participants will be requested to perform this protocol 3 times weekly. Training progression will be implemented by increasing the number of repeats from four repetitions during weeks 1 and 2, to five repetitions during weeks 3 and 4, to six repetitions during weeks 5 and 6. Finally, during week 7 participants will still perform six repetitions but interspersed by only 20 s recovery.
Study NCT03228914 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxymetazoline
Description: Pledgets will be soaked in 0.05% oxymetazoline solution Two pledgets with the associated medication will be placed into the nasal cavity; one along the floor of the nose and another directed towards the middle meatus.
Study NCT03228914 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: Pledgets will be soaked in 1:1000 epinephrine solution Two pledgets with the associated medication will be placed into the nasal cavity; one along the floor of the nose and another directed towards the middle meatus.
Study NCT02805998 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based CBT-I
Study NCT02805998 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as Usual
Study NCT02805998 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Study NCT01107015 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tailored Patient Intervention
Description: Patients select one of two mobile phone models, receive a one-year unlimited mobile phone data and phone service plan, receive the study treatment phone software and have access to the web-based individual patient portal. Given system-driven guidance on when to test blood glucose (bg) based on disease status, medication regimen, and time of poorest control. Patients enter bg data, carbohydrates consumed, diabetes medications taken and miscellaneous comments regarding diabetes self-care. Messages are sent to the patient's mobile phone giving feedback on entered data. Entered data are captured in real-time in the web-based logbook. Patients may provide their PCPs with printed copies of their logbooks and other information but physicians do not have access to the patient portal system. Patient action plans summarizing the patient-entered data and identifying possible self-management actions for improving their diabetes control are electronically sent to the patients every 2.5 months.
Study NCT01107015 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Patient-physician intervention
Description: Patients select one of two mobile phone models, receive a one-year unlimited mobile phone data and phone service plan, receive the study treatment phone software and have access to the web-based individual patient portal. Given system-driven guidance on when to test blood glucose (bg) based on disease status, medication regimen, and time of poorest control. Patients enter bg data, carbohydrates consumed, diabetes medications taken and miscellaneous comments regarding diabetes self-care. Messages are sent to the patient's mobile phone giving feedback on entered data. Entered data are captured in real-time in the web-based logbook. PCPs are provided access to a web portal where they may choose to review their patients' electronic logbooks. This is raw patient data that have not been analyzed.
Study NCT01107015 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Patient and PCP intervention with analyzed data
Description: Patients select one of two mobile phone models, receive a one-year unlimited mobile phone data and phone service plan, receive the study treatment phone software and have access to the web-based individual patient portal. Given system-driven guidance on when to test blood glucose (bg) based on disease status, medication regimen, and time of poorest control. Patients enter bg data, carbohydrates consumed, diabetes medications taken and miscellaneous comments regarding diabetes self-care. Messages are sent to the patient's mobile phone giving feedback on entered data. Entered data are captured in real-time in the web-based logbook. PCPs are provided access to a secure web portal where they can see their patients' electronic logbooks. PCPs are provided with data analysis reports. The PCP is reminded that all data analysis is based on patient-entered, unvalidated data. The PCP has the option to use this information and remains responsible for all treatment decisions.
Study NCT00458835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide
Study NCT00004980 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: a total of 132 minutes of stimulation at one hertz, motor threshold set at 80%, delivered to TP3 scalp site
Study NCT00004980 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham stimulation
Description: 132 minutes of stimulation given at 80% motor threshold with coil tilted single wing 45 degrees away from scalp deliverd to TP3 site
Study NCT02248376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gel
Description: Patients aged of more than 18 years-old coming for a natural miscarriage who will have the stick gel application at the end of the scraping surgery.
Study NCT02252861 — intervention group
Intervention type: OTHER
Intervention: Percutaneous Left Atrial Appendage Closure in routine care
Description: The inclusion in the database induces no specific intervention. Percutaneous Left Atrial Appendage Closure is performed for patient care. No specific intervention is performed specifically for the database. Neither left atrial appendage closure procedure nor patient follow up are modified by patient inclusion in the database.
Study NCT01575990 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Making A Decision About CRC Screening
Description: Targeted by age and gender with 3 components.~1. Educational component~2. Values clarification exercise~3. Individualized decision making worksheet~The intervention or control condition is administered before the index visit with the patient's provider.
Study NCT01575990 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Drivers 65 Plus
Description: This text booklet is provided as an attention control for those in the control arm and like the intervention is administered prior to the index visit with the patient's provider.
Study NCT00740051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: 5mg once daily
Study NCT02413762 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT00795574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: infliximab
Description: Dosing is 5mgs/kg at weeks 0,2 and 6 to complete loading dose of drug and then every 8 weeks thereafter until end of treatment phase.
Study NCT00795574 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: 5mgs /kg given IV over a minimum of 2 hours at weeks 0,2 and 6 to complete loading dose and then every 8 weeks during maintenance treatment period.
Study NCT03212261 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3RP-Lymphoma
Description: An adapted version of the Relaxation Response Resiliency Program (3RP) for individuals who have recently completed treatment for lymphoma.
Study NCT00795574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Comparator
Description: 5mgs /kg given IV over a minimum of 2 hours at weeks 0,2 and 6 to complete loading dose and then every 8 weeks during maintenance treatment period.
Study NCT00747513 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle program
Description: a comprehensive program designed to encourage healthier food choices and eating habits and increased physical activity among children, by use of school, family and community measures.
Study NCT04439786 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: the control group will be given the same volume of saline.
Study NCT04439786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine
Description: the experimental group will be given 1-1.5mg/kg lidocaine and then 2mg/kg/h
Study NCT02682758 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Xenon
Description: Wash-in of xenon for maintenance of anaesthesia
Study NCT02112201 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated intervention for parents and adolescent girls
Description: The intervention will consist of individually administered preventive curriculum for adolescent girls involved in the juvenile justice system that integrally addresses delinquency, drug abuse, and trauma exposure, along with group-based training and support for parents.
Study NCT01067235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BF2.649
Description: BF2.649 oral capsules at 10, 20 or 40 mg/day associated with Modafinil Placebo capsules for 8 weeks
Study NCT01067235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BF2.649 add on Modafinil
Description: BF2.649 oral capsules at 10, 20 or 40 mg/day associated with Modafinil capsules at 200 mg per day for 8 weeks
Study NCT00740051 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Linagliptin Placebo
Description: 0 mg placebo comparator for part 1 of study (to 18 weeks)
Study NCT00740051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: 1-4mg for part 2 of study (weeks 19-52)
Study NCT00308776 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cholecystokinin (CCK) infusion
Description: Participants will begin infusion with a normal saline solution. After 10 minutes of saline infusion, participants will eat a small bowl of tomato soup, followed 20 minutes later by a 15-minute infusion of saline plus CCK.
Study NCT00308776 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Saline infusion
Description: Participants will begin infusion with a normal saline solution. After 10 minutes of saline infusion, participants will eat a small bowl of tomato soup, followed 20 minutes later by a 15-minute infusion of saline only.
Study NCT04990076 — intervention group
Intervention type: PROCEDURE
Intervention: Hysterectomy
Description: Surgery includes different types of hysterectomy: vaginal hysterectomy, total abdominal hysterectomy and laparoscopic or Robotic hysterectomy. The type of hysterectomy does not influence histological outcome, as long as the uterus is removed in one part (no power morcellation). Indications for surgery and the type of surgery are according to the departments' protocols. If the patient is deemed to be inoperable due to the extent of the disease, a representive biopsy (e.g. trucut biopsy) will be accepted if sufficiently motivated by the oncology team.
Study NCT00862602 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepping Up to Health
Description: Internet-mediated pedometer-based intervention with gradually increasing goals and feedback on step counts. Also includes educational content targeted at women who have had gestational diabetes about exercise, diet \& nutrition and prevention.
Study NCT03139201 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OxyAqua
Description: OxyAqua (olifilcon D) silicone hydrogel soft contact lens
Study NCT03139201 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Si-Hy
Description: Si-Hy (oliflcon B) silicone hydrogel soft contact lens
Study NCT02498821 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Chest X-ray
Description: A Chest X-ray will be taken after healthcare providers have inserted the PICC to make sure it is in the correct location. The X-ray can tell your healthcare providers where the PICC is and whether is has been inserted correctly.
Study NCT02078037 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arctic Sun cooling device
Description: The Arctic Sun® 5000 Temperature management systems (Bard Medical), a non- invasive, surface cooling technology that allows rapid and precise manipulation of core body temperature will be employed to maintain normothermia (normal temperature) in patients with ICH randomized to the treatment group.
Study NCT02078037 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Patient will be given standard fever management (acetaminophen + cooling blanket at the discretion of the treating physician)
Study NCT03864432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemigliptin 25mg
Description: Gemigliptin 50mg 1/2T
Study NCT03864432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemigliptin 50mg
Description: Gemigliptin 50mg 1T
Study NCT03864432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemigliptin 100mg
Description: Gemigliptin 50mg 2T
Study NCT03864432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemiglptin 50mg multiple dose
Description: Gemigliptin 50mg 1T \* 10days
Study NCT00107588 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reinforcement for homework completion
Description: Provides contingent reinforcement for engaging in homework activities designed to enhance coping skills
Study NCT00107588 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reinforcement for Abstinence
Description: Provides contingent reinforcement for submitting marijuana-free urine specimen
Study NCT00107588 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Case Management
Description: Will control for the effect of therapist-client contact by providing supportive case management as an active control condition.
Study NCT03590470 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation of a nurse-led model of care
Description: A nurse-model of care consisting of a specifically trained geriatric nurse expert, communication and quality improvement tools will be implemented in 11 nursing homes in the German speaking part of Switzerland
Study NCT00530166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-18054478
Description: 3(100 mg) tablets once daily for 12 weeks
Study NCT00530166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sham comparator
Description: 3(100 mg) tablets once daily for 12 weeks